Tumour-derived interleukin 1alpha (IL-1alpha) up-regulates the release of soluble intercellular adhesion molecule-1 (sICAM-1) by endothelial cells. by Fonsatti, E. et al.
British Joumal ofCancer(1997) 76(10), 1255-1261
© 1997 Cancer Research Campaign
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release of soluble intercellular adhesion molecule-I
(sICAM-I) by endothelial cells
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Summary Levels of circulating soluble intercellular adhesion molecule-1 (sICAM-1) are elevated in patients affected by solid malignancies;
however, the cellular sources generating high levels ofsICAM-1 remain to be characterized. Using conditioned media (CM) from seven ICAM-
1-positive or -negative neoplastic cells, we demonstrate that tumour-derived interleukin 1a (IL-1a) significantly (P < 0.05) up-regulates the
release of sICAM-1 by human umbilical vein endothelial cells. The intensity of the effect correlated with the amounts of IL-la detectable in
CM. Levels of ICAM-1 mRNA were also up-regulated by tumour-secreted IL-i a. The up-regulation of the shedding of sICAM-1 and of its
expression at protein and mRNA level were completely reversed by the addition of anti-IL-i a neutralizing antibodies. Consistent with the in
vitro data, tumour endothelia were strongly stained for ICAM-1 compared with autologous normal tissue endothelia. Taken altogether, our
observations reveal an IL-la-mediated tumour-endothelium relationship sustaining the shedding of sICAM-1 by endothelial cells. This is a
general phenomenon in solid malignancies that correlates with the ability of neoplastic cells to secrete IL-1a rather than with their expression
of ICAM-1 and/or histological origin. sICAM-1 has been previously shown to inhibit LFA-1/ICAM-1-mediated cell-cell interactions; therefore,
the ability of neoplastic cells to secrete IL-1a is likely to represent a mechanism for their escape from immune interaction.
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Intercellular adhesion molecule-I (ICAM-1/CD54) is an 80-
1 1O-kDa cell membrane glycoprotein that belongs to the immuno-
globulin supergene family (Staunton et al, 1988). By binding to its
counter-receptor, lymphocyte function-associated antigen-I (LFA-
1/CD lla), ICAM-1 strengthens cell-cell interactions required for
the generation of a variety of immune responses (Maio and Del
Vecchio, 1992). In addition to its expression on immune cells,
ICAM-1 is broadly distributed in normal tissues (Smith and
Thomas, 1990), is selectively expressed in human malignancies
(Maio et al, 1990; Natali et al, 1990; Vainky et al, 1990) and its
expression can be regulated by various stimuli on normal (Dustin
et al, 1986; Maio et al, 1989; Hashimoto et al, 1994) and
neoplastic cells (Schwaeble et al, 1993; Altomonte et al, 1993).
Constitutive levels ofa soluble form ofICAM-I (sICAM-1) have
been identified in the serum ofhealthy subjects (Rothlein etal, 1991;
Seth et al, 1991), and elevated amounts are detectable in inflamma-
tory (Seth et al, 1991; Jones et al, 1995) and autoimmune (Schopfet
al, 1993; Sharief et al, 1993) disorders. Furthermore, high levels of
sICAM-1 are detectable in malignancies of different histotype and
correlate with disease progression (Tsujisaki et al, 1991; Altomonte
et al, 1992; Banks et al, 1993; Pui et al, 1993). This latter finding
suggested thatelevated levels ofsICAM-1 represent an unfavourable
prognostic marker in human neoplasias and that sICAM-1 can be
used tomonitortheclinical course ofdisease (Altomonte etal, 1992).
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sICAM-1 inhibits non-MHC-restricted (Altomonte et al, 1993)
and MHC-restricted (Becker et al, 1993) lysis of neoplastic cells
by cytotoxic cells and blocks the adhesion of peripheral blood
mononuclear cells to malignant cells (Hansen et al, 1994) and to
activated endothelia (Hashimoto et al, 1994; Rieckmann et al,
1995). Thus, sICAM-1 may provide neoplastic cells with different
mechanisms ofescape from cell-mediated immune surveillance.
ICAM-1-positive neoplastic cells release sICAM-1 (Tsujisaki et
al, 1991; Kageshita et al, 1992), suggesting that they may
contribute to the high levels of sICAM-1 detectable in cancer
patients. Nevertheless, elevated levels of sICAM-1 are also
present in patients affected by ICAM-1-negative malignancies,
such as sarcomas (Natali et al, 1990; Pui et al, 1993), and ovary
(Vainky et al, 1990; Banks et al, 1993) and bladder (Banks et al,
1993; Nouri et al, 1996) carcinomas. Moreover, higher levels of
sICAM-1 have been found in sera ofpatients affected by ICAM-1-
negative renal cell carcinomas than ICAM-1-positive tumours of
similarhistotype (Heicappell et al, 1994). In view ofthese consid-
erations, it is critical to identify the cellular sources that may
contribute to the release of sICAM-1 in ICAM-1-negative malig-
nancies and the mechanism(s) underlying such a phenomenon.
Endothelial cells constitutively express ICAM-1, shed very low
levels of sICAM-1 (Hashimoto et al, 1994) and are highly repre-
sented within the tumour massowing to the abundant angiogenesis
occurring in solid malignancies (Fox et al, 1996). Therefore, using
conditioned media (CM) from ICAM-1-negative or -positive
neoplastic cells, we investigated whether endothelial cells may
contribute to the generation of the elevated levels of sICAM-1
detectable in human malignancies and the mechanism(s) under-
lying the functional relationship between malignant cells and
endothelial cells for the shedding of sICAM-1.
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Figure 1 Shedding of sICAM-1 by HUVECs cultured in CM from different
neoplastic cells. HUVECs (2 x 106) were cultured in 3 ml of CM from indicated
neoplastic cells. After a 24-h incubation, culture supernatants were harvested
and analysed using ELISA to quantify sICAM-1. In control cultures (---),
HUVECs were grown under the same expenmental conditions but in CM from
HUVECs. Data represent the mean value ± s.d. of the amounts of sICAM-1
detected in three independent experiments, subtracted of the amount of
sICAM-1 present in CM added to cultures. *P< 0.05 vs control (-- -)
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MATERIALS AND METHODS
Isolation of human umbilical vein endothelial cells
(HUVECs), cell lines and preparation of CM
Primary cultures of HUVECs were prepared as described previ-
ously (Brasoveanu etal, 1995). The purity ofHUVEC preparations
was assessed by the anti-endoglin MAb MAEND3, which stained
100% of cultured cells. All experiments were performed using
confluent monolayers ofHUVECs at third passage in culture.
The melanoma cell line Colo 38 (Altomonte et al, 1993), the
rhabdomyosarcoma cell line A-204, the colon adenocarcinoma cell
line DLD-1, the osteosarcoma cell line MG-63, the ovary adeno-
carcinoma cell line SK-OV-3, the fibrosarcoma cell line HT-1080
andthe epithelial bladdercarcinoma cell line5637,purchased from
American Type Culture Collection (ATCC, Rockwille, MD, USA),
were grown in RPMI-1640 medium supplemented with 10% fetal
calf serum (FCS) and 2 mM L-glutamine.
CM were prepared by seeding neoplastic cells and HUVECs in
T75 flasks; when cells reached semiconfluence, supernatants were
replaced with 10 ml of fresh RPMI-1640 medium and, after 24 h,
supematants were collected, centrifuged to remove cell debris,
filtered through a 0.22-jim acetate filter, aliquoted and immedi-
ately stored at - 80°C until use as CM and in ELISA to quantify
sICAM-1 and the presence of cytokines. No loss of biological
activity was observed over a 3-month period.
MAb and conventional antisera
The anti-ICAM-l MAb 84H10, the anti-LFA-3 MAb TS2/9 and
the anti-endoglin MAb MAEND3 were developed and character-
ized as described previously (Sanchez-Madrid et al, 1982;
Makgoba et al, 1988; Altomonte et al, 1996). The anti-HLA
class I MAb W6/32 was purchased from ATCC. Dichlorotri-
azynylaminofluorescein-conjugated F(ab')2 fragments of goat
anti-mouse Ig antibodies, Fc fragment specific and ChromePure
mouse IgG were purchased from Jackson ImmunoResearch
Laboratories, (West Grove PA, USA). IL-la, IL-15, TNF-a and
IFN-y neutralizing antibodies were purchased from Genzyme
(Cambridge, MA, USA).
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Figure 2 Modulation of ICAM-1, HLA class I and LFA-3 expression on
HUVECs cultured in CM from different neoplastic cells. HUVECs (2 x 106)
were cultured in 3 ml of CM from indicated neoplastic cells. After a 24-h
incubation, cells were harvested, washed twice with Hanks' balanced salt
solution, resuspended in phosphate-buffered saline (0.1%), bovine serum
albumin (0.02%), sodium azide and sequentially incubated with anti-ICAM-1
MAb 84H10, anti-HLA class I MAb W6/32 or anti-LFA-3 MAb TS2/9 and with
dichlorotriazynylaminofluorescein-conjugated F(ab')2 fragments of goat anti-
mouse IgG xenoantibodies; cells were then analysed by flow cytometry. In
control cultures (control), HUVECs were grown under the same experimental
conditions but in CM from HUVECs. Data represent the mean value ± s.d. of
mean fluorescence intensity values obtained in three independent
experiments. *P< 0.05 vs control
Culture of HUVECs in the presence of CM
HUVECs (5 x 10 ml-') were seeded in 4 ml ofculture medium in
T25 flasks; the next day the medium was removed and 3 ml ofCM
was added with or without either a combination of 50 jg ml-'
polyclonal rabbit anti-human IL-la and anti-human IL-lI anti-
bodies, neutralizing 50 IU of IL-la and IL- 1P (equivalent to
500 pg), or 10 jl ofpolyclonal rabbit anti-human TNF-aantibody,
neutralizing 1000 IU of TNF-a (equivalent to 100 ng), or
5 jg ml-' of monoclonal mouse anti-human IFN-y antibody,
neutralizing 5 x 106 IU of IFN-y (equivalent to 500jg). After a
24-h incubation, supematants were collected, centrifuged to
remove cell debris, filtered through a 0.22-jim acetate filter,
aliquoted and immediately stored at -80°C until use in enzyme-
linked immunosorbent assay (ELISA) to quantify sICAM-1.
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Figure 3 Effect of neutralizing antibodies on the shedding of sICAM-1 by
HUVECs cultured in CM from HT-1 080 cells. HUVECs (2 x 106) were cultured
in 3 ml of CM from HT-1 080 cells in the presence or absence of a
combination of anti-IL-1a/,-polyclonal antibodies or anti-TNF-a polyclonal
antibodies. After a 24-h incubation, cells and culture supernatants were
harvested separately and used to assess levels of cell surface ICAM-1 (A)
and of sICAM-1 (B) as previously described. In control cultures (control),
HUVECs were grown under the same experimental conditions but in CM from
HUVECs and without neutralizing antibodies. Data represent the mean
values ± s.d. of mean fluorescence intensity values of ICAM-1 and of
amounts of sICAM-1 obtained in three independent experiments.* P < 0.05 vs
control and vs IL-iaI0-neutralizing antibody-supplemented cultures
Serological assays
Indirect immunofluorescence was performed as previously
described (Brasoveanu et al, 1996). Results are expressed as mean
values of fluorescence intensity on a linear scale. A sample was
classified as positive when more than 10% of the cells were
stained with the relevant MAb and the mean value offluorescence
intensity was higher than 20. The percentage of cells stained by
isotype-matched mouse Ig and the mean values of fluorescence
intensity were lower than 10% and 20, respectively, on all cell
lines tested.
In three distinct assays, A-204, SK-OV-3, HT-1080 and 5637
cells neither expressed ICAM-1 nor released sICAM-1; in
contrast, mean values of mean fluorescence intensity of ICAM-1
expression and ofsICAM-1 release were 29 ± 12, 145 ± 78, 25 ± 8,
50 ± 3 and 4.1 ± 2.2, 11.2 +2.5, 4.3 ±4.5, 5.8 ± 1.5 ng ml, for
HUVECs, Colo 38, DLD-1, MG-63 cells respectively.
The double determinant immunoassay to measure sICAM-1
was performed using an ELISA kit from Genzyme. Human IL- a,
IL-1,3, TNF-a, TNF-P and IFN-,y were quantitated using ELISA
kits purchased from Research and Diagnostic Systems
(Minneapolis, MN, USA).
Indirect immunoperoxidase stain was performed using primary
MAb at concentration ranging from 10 to 30 gg ml and a commer-
cially available avidine-biotin kit from Vector (Burlingame, CA,
USA) as described previous (Brasoveanu et al, 1996).
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Figure 4 Effect of neutralizing antibodies on the shedding of sICAM-1 by
HUVECs cultured in CM from 5637 cells. HUVECs (2 x 106) were cultured in
3 ml of CM from 5637 cells in the presence or absence of a combination of
anti-IL-ia/4-polyclonal antibodies or anti-TNF-ax polyclonal antibody. After a
24-h incubation, cells and supernatants were harvested separately and used
to assess levels of cell surface ICAM-1 (A) and of sICAM-1 (B) as previously
described. In control cultures (control), HUVECs were grown under the same
experimental conditions but in CM from HUVECs and without neutralizing
antibodies. Data represent the mean values ± s.d. of mean fluorescence
intensity values of ICAM-1 and of amounts of sICAM-1 obtained in three
independent experiments. *P < 0.05 vs control and vs IL-1a/,-neutralizing
antibody-supplemented cultures
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Figure 5 Northern blot analysis of ICAM-1 mRNA in HUVECs cultured in
CM from HT-1080 and 5637 cells. HUVECs (2 x i06) were cultured in CM
from HT-1080 and 5637 cells with or without neutralizing antibodies, as
described in the legends to Figures 3 and 4 respectively. After a 24-h
incubation cells and culture supernatants were harvested separately and
levels of cell surface ICAM-1 and of sICAM-1 were analysed as previously
described. Then total RNA was extracted from HUVECs (1 x 106) and
separated (5 ,ug) on a 1% agarose-formaldehyde gel, transferred onto a
nylon membrane and hybridized with [a32P]dCTP radiolabelled cDNA probes
for ICAM-1 and f-actin. In control cultures (control), HUVECs were grown
under the same experimental conditions but in CM from HUVECs and
without neutralizing antibodies. Filters were then processed for
autoradiography. Scanning densitometric values for ICAM-1, adjusted for
differences in 3-actin are: control = 1 (arbitrary unit); HT-1080 = 23.98; HT-
1080 + anti-TNF-a = 26.53; HT-1080 + anti-IL-1a/P
= 2.26 (A); control = 1
(arbitrary unit); 5637 = 22.65; 5637 + anti-TNF-a = 23.28; 5637 + anti-IL-
1a/P
= 2.19 (B). Levels of ICAM-1 mRNA were analysed using HUVECs
derived from one of the experiments shown in Figures 3 and 4
British Journal ofCancer (1997) 76(10), 1255-1261
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Northern blot analysis
Northern blot analysis was performed as described previously
(Brasoveanu et al, 1995). cDNA probe for ICAM-1 was a 1.8-kb
fragment of the full length cDNA cut from pGEM by the restric-
tion enzymes KpnI and Sall, provided by TA Springer, Center for
Blood Research, Boston, MA, USA. Scanning densitometric
values were obtained by a scanning densitometer GS300 from
Hoefer Scientific Instruments (San Francisco, CA).
Tissue samples
Surgical biopsies of bladder carcinomas were obtained from
patients who had undergone surgery and who had not received
treatment in the previous two months. Normal bladder samples
were excised far from transformed tissue. Tissue samples were
processed as described (Brasoveanu et al, 1996).
Statistical analysis
Datawereanalysedbythe Student's paired t-testusing the StatWorks
statistical package from Cricket Software (Philadelphia, PA, USA).
Differences with P < 0.05 were considered statistically significant.
RESULTS
CM-mediated up-regulation of sICAM-1 release by
HUVECs
To investigate whether soluble factor(s) released by neoplastic
cells may modulate the constitutive shedding of sICAM-l by
endothelial cells, HUVECs were cultured for 24 h in the presence
of CM from ICAM-1-negative or -positive neoplastic cells, then
culture supernatants were assayed for their content ofsICAM-1 in
three independent experiments.
Figure 1 shows that the mean values ± s.d. of the amounts of
detected sICAM-1, subtracted from the amount of sICAM-1
present in CM added to cultures, were 4.7 ± 1.5, 2.5 ± 1, 6.6 ± 0.5,
7 ± 0.9, 6.8 ± 0.4, 8.2 ± 0.6, 11.3 ± 1.9 and 14.9 ± 1.2 ng ml-', for
CM from HUVECs, Colo 38, A-204, DLD-1, MG-63, SK-OV-3,
HT-1080 and 5637 respectively. In the CM used, the shedding of
sICAM-1 by HUVECs was significantly enhanced by CM from
HT-1080 (P = 0.004) and 5637 (P = 0.001) cells, compared with
CM from HUVECs (Figure 1). Moreover, the amounts ofsICAM-
1 released by HUVECs cultured in CM from 5637 cells were
significantly (P = 0.02) higher than those of.HUVECs cultured in
CM from HT-1080 cells (data not shown).
CM-mediated up-regulation of ICAM-1 expression by
HUVECs
As CM from selected neoplastic cells enhanced the release of
sICAM-1 by HUVECs, we investigated whether a corresponding
increase in the expression of ICAM-1 by HUVECs could be
observed. To this end, HUVECs from the experiments described in
Figure 1 were assayed for their expression ofICAM-1.
The mean values ± s.d. of mean fluorescence intensity of the
constitutive expression of ICAM-1, HLA class I and LFA-3 by
HUVECs were 29± 12, 120 ± 12 and 21 ± 5 respectively (data not
shown). The mean values ± s.d. of mean fluorescence intensity of
ICAM-1 expression on HUVECs cultured in CM from HUVECs,
Colo 38, A-204, DLD-l, MG-63, SK-OV-3, HT-1080 and 5637
were30±6,32±6,34±3,36±6,75±24, 148±60,212± 17 and
523 ± 130 respectively. ICAM-1 expression was significantly
higher on HUVECs grown in CM from MG-63 (P = 0.05), HT-
1080 (P = 0.03) and 5637 (P = 0.01) cells, compared with CM
from HUVECs (Figure 2).
The mean values ± s.d. of mean fluorescence intensity of HLA
class I expression on HUVECs cultured in CM from HUVECs,
Colo 38, A-204, DLD-1, MG-63, SK-OV-3, HT-1080 and 5637
were 132±35, 147±39, 138±50, 155±41, 152±39, 193±64,
181 ± 55 and 247 ± 48 respectively and were significantly higher
on HUVECs grown in CM from HT-1080 (P = 0.01) and 5637
(P = 0.005) cells than CM from HUVECs (Figure 2).
Constitutive levels of cell-surface LFA-3 were not affected by
culturing HUVECs in either ofthe CM used (Figure 2).
Detection of cytokines in CM
To characterize tumour-derived factor(s) that may be responsible
for the CM-mediated up-regulation of sICAM-1 release by
HUVECs, CM were assayed for the presence of IL-la, IL-1p,
IFN-y, TNF-a and TNF-,B. IL-la was detectable only in CM from
HT-1080 and 5637 cells, with values of72 pg ml-' and 278 pg ml'
respectively; no detectable levels of the other cytokines tested
were found (data not shown).
Anti-IL-iac/ antibodies inhibition of CM-induced
up-regulation of sICAM-1 release by HUVECs
To determine whether IL-la released by HT-1080 and 5637 cells
is responsible forthe up-regulation ofthe shedding ofsICAM-1 by
HUVECs, cytokine activity neutralization assays were performed.
Results from three independent experiments demonstrated that
culturing HUVECs in CM from HT-1080 (Figure 3) and 5637
(Figure 4) cells in the presence of a combination of anti-IL- IcX/,
neutralizing antibodies, completely abolished CM-induced up-
regulation of the shedding of sICAM-1 by HUVEC. Accordingly,
anti-IL-la/3 neutralizing antibodies completely reverted CM-
induced increase of ICAM-1 expression by HUVECs (Figures 3
and 4). Neither anti-TNF-a (Figures 3 and 4) nor anti-IFN-y
(data not shown) neutralizing antibodies inhibited CM-induced
up-regulation of sICAM-1 release and of ICAM-1 expression
by HUVECs.
Anti-IL-la/, antibodies inhibition of CM-induced
up-regulation of ICAM-1 mRNA levels in HUVECs
Northern blot analysis revealed that levels of ICAM-1 mRNA
were elevated in HUVECs cultured in CM from HT-1080 and
5637 cells compared with CM from HUVECs (Figure 5). The
increase in the levels of ICAM-1 mRNA was completely abol-
ished by the addition of anti-IL-l a/p neutralizing antibodies to
CM from HT-1080 and 5637 cells (Figure 5). In contrast, neither
anti-TNF-a (Figure 5) nor anti-IFN-y (data not shown) neutral-
izing antibodies did it.
Analysis of ICAM-1 expression in normal urinary
bladder and autologous bladder carcinomas
To investigate whether endothelial cells of blood vessels within
the tumour mass may express elevated levels of ICAM-1
compared with those in benign tissues, cryostat sections from five
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Figure 6 Expression of ICAM-1 in normal urinary bladder and autologous malignant tissue as revealed by indirect avidine-biotin immunoperoxidase staining
on 4-,um cryostat sections using MAb 84H10. In normal bladder, ICAM-1 specific stain is detected in scattered cells located in the submucosa (A) and
occasionally at low level in small vessels of the muscular layers (B). In the autologous tumour tissue, MAb 84H10 decorates interstiiial cells and
microvasculature (C) as well as the majority of the vessels of the muscular layers (D). Differences in ICAM-1 vascular expression are also detected in normal
submucosa (E) and tumour submucosa (F). Mayer's haematoxylin nuclear counterstain (bar = 23 ,um)
normal urinary bladder and autologous bladder carcinomas were
stained for ICAM-1 by MAb 84H10. Representative data are
shown in Figure 6, demonstrating that in normal bladder tissues
only isolated blood vessels within the chorion tissue and the
muscular layer were weakly and heterogeneously stained by MAb
84H10; moreover, scattered cells located in the submucosa stained
positive for ICAM-1. In contrast, in the autologous tumour tissue,
all detectable blood vessels in the chorion tissue were strongly and
homogeneously stained by MAb 84H10, which also stained, to a
layer (Figure 6). Epithelial and interstitial cells were also variably
stained by MAb 84H10 in selected malignant tissues investigated
(Figure 6 and data not shown).
DISCUSSION
In this study we present the first evidence demonstrating that IL-
1 x, secreted at detectable levels by ICAM-1-negative HT-1080
fibrosarcoma cells and 5637 bladder carcinoma cells, significantly
lower extent, the majority of blood vessels within the muscular up-regulates the release of sICAM-1 by cultured endothelia. The
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increase in sICAM-1 release by HUVECs was significantly (P =
0.02, data not shown) higher with CM from 5637 cells than with
CM from HT-1080 and was completely abolished by anti-IL-la
neutralizing antibodies. In addition, using serial dilutions of CM
from HT-1080 and 5637 cells, the up-regulation ofthe shedding of
sICAM-1 by HUVECs was found to be dose-dependent (data not
shown). These findings demonstrate that the amount of sICAM-l
released by HUVECs depends on the level oftumour-secreted IL-
la and that no additional soluble factors tested or released by the
investigated neoplastic cells are responsible for the observed
increase. ICAM-1 expression and level of ICAM-1 mRNA were
also up-regulated by CM from HT-1080 and 5637 cells; both
effects were completely abolished by anti-IL-la neutralizing anti-
bodies. All these data suggest that tumour-derived IL-la activates
the transcriptional machinery regulating ICAM-1 gene expression
that leads to the shedding of sICAM-1 by HUVECs. Although the
molecular mechanism(s) underlying ICAM-1 release from the cell
membrane remains to be elucidated (Ehlers and Riordan, 1991),
the effects of tumour-derived IL-la are unlikely to represent a
transient phenomenon as levels of sICAM-1 and ICAM-1 expres-
sion remained elevated in HUVECs cultured for more than 2
weeks in CM from HT-1080 cells and repeatedly tested for their
release ofsICAM-l and ICAM-1 expression (data not shown).
Previous studies have reported that exogenous (Dejana et al,
1988) ortumour-derived (Burrow et al, 1991; Kaji et al, 1995) IL-
la increases the adhesion of neoplastic cells to HUVECs in vitro
and enhances the metastatic potential ofneoplastic cells (Giavazzi
et al, 1990), and that IL-1 receptor blockade reduces the number
and the size of metastases (Vidal-Vanaclocha et al, 1994). These
tumour spread-promoting effects of IL-la are independent from
endothelial ICAM-1 because of the absence of LFA-1 in solid
malignancies (Altomonte et al, 1993; Futagami-Mizoguchi et al,
1993). Nevertheless, IL-la-mediated up-regulation of ICAM-1
expression on endothelia increases immune cells' adhesion and
extravasation from blood vessels (Bevilacqua, 1993) and, thus,
may contribute to neoplastic cells' destruction by immune effector
cells, providing a local inhibition of tumour progression. These
counteracting effects ofIL-i a on local tumourprogression may be
explained by our demonstration that tumour-derived IL-la up-
regulates the constitutive shedding of sICAM-1 by endothelia. In
fact, high levels ofsICAM-1 generated by tumour-derived IL-la-
activated endothelia may decrease immune cells' adhesion to acti-
vated endothelia and their subsequent extravasation at tumour
sites; moreover, they may also impair LFA-l/ICAM-l-mediated
non-MHC- and MHC-restricted cytotoxicity of malignant cells
(Altomonte et al, 1993; Becker et al, 1993).
The evidence that endothelial cells release sICAM-I after being
targeted by tumour-derived IL-la is also intriguing in view ofthe
marked angiogenesis occurring in solid tumours (Fox et al, 1996)
and of the angiogenic activity of IL-la (Fox et al, 1996). In fact,
tumour-derived IL-1a may generate sequential events leading to
the neoformation of blood vessels and to the consequent up-regu-
lation of sICAM-I release by IL-la-activated tumour endothelia.
In this model, IL-la should represent the principal mediator of
sICAM-I release by endothelia, and angiogenesis itself should not
significantly contribute to the up-regulation of the levels of
sICAM-l. In fact, in actively proliferating HUVECs, levels ofcell
membrane ICAM-I and of sICAM-l do not differ from those of
resting HUVECs (E Fonsatti and Maio, unpublished).
The strong staining for ICAM-1 detected in bladder carcinoma
endothelia, compared with endothelia within autologous normal
bladder tissues, is consistent with the in vitro data obtained with
bladder carcinoma cells 5637 and strongly supports the existence
of a tumour-endothelia relationship controlling ICAM-1 expres-
sion and shedding by endothelial cells in vivo. This hypothesis is
further supported by the lack ofmodulation ofICAM-I expression
and shedding of sICAM-l by HUVECs, that we observed using
CM from ICAM-1-positive melanoma cells Colo 38 and by the
demonstration that staining for ICAM-1 was similar in blood
vessels within skin melanomas as compared with autologous
normal skin (Erhard et al, 1996). Levels of circulating sICAM-1
are elevated in melanoma patients (Altomonte et al, 1992); there-
fore, it can be argued that melanoma cells generate the largest
amount ofdetectable sICAM-1 and thatendothelial cells provide a
limited support to this event.
Our data, in combination, unveil an IL-la-mediated tumour-
endothelia relationship that influences the constitutive shedding of
sICAM-1 by endothelial cells, that may contribute to the elevation
ofthe levels ofsICAM-I inICAM-l-negative malignancies and that
may add to those detectable in ICAM-l-positive malignancies. The
identification ofIL-la as the tumour-derived soluble mediator that
up-regulates the shedding of sICAM-1 by endothelial cells demon-
strates that IL-la release by neoplastic cells should be accounted as
an additional feature that impairs host-tumour interactions and
favours neoplastic cells' escape from immune surveillance.
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